6 Spam-Free Article(s) Found
Sort:
Date
Filter:
7d
Article Searches
Here's Why GSK (GSK) Gained But Lagged the Market Today https://www.zacks.com/stock/news/2247009/here-s-why-gsk-gsk-gained-but-lagged-the-market-today?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2247009 Mar 27, 2024 - GSK (GSK) closed at $42.99 in the latest trading session, marking a +0.47% move from the prior day.
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates https://www.zacks.com/stock/news/2246577/aeterna-zentaris-aezs-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2246577 Mar 27, 2024 - AEterna Zentaris (AEZS) delivered earnings and revenue surprises of -19.59% and 2,925%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
GSK (GSK) Stock Moves -0.09%: What You Should Know https://www.zacks.com/stock/news/2246352/gsk-gsk-stock-moves-0-09-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2246352 Mar 26, 2024 - GSK (GSK) closed at $42.79 in the latest trading session, marking a -0.09% move from the prior day.
Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates https://www.zacks.com/stock/news/2245649/equillium-inc-eq-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2245649 Mar 25, 2024 - Equillium (EQ) delivered earnings and revenue surprises of 58.82% and 4.08%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
GSK or TECH: Which Is the Better Value Stock Right Now? https://www.zacks.com/stock/news/2245610/gsk-or-tech-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2245610 Mar 25, 2024 - GSK vs. TECH: Which Stock Is the Better Value Option?
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US https://www.zacks.com/stock/news/2244405/gsk-follows-rivals-to-cap-out-of-pocket-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2244405 Mar 21, 2024 - GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.

Pages: 1

Page 1